TY - JOUR
T1 - Efficacy of the eHealth application Oncokompas, facilitating incurably ill cancer patients to self-manage their palliative care needs
T2 - A randomized controlled trial
AU - Schuit, Anouk S
AU - Holtmaat, Karen
AU - Lissenberg-Witte, Birgit I
AU - Eerenstein, Simone E J
AU - Zijlstra, Josée M
AU - Eeltink, Corien
AU - Becker-Commissaris, Annemarie
AU - van Zuylen, Lia
AU - van Linde, Myra E
AU - Menke-van der Houven van Oordt, C Willemien
AU - Sommeijer, Dirkje W
AU - Verbeek, Nol
AU - Bosscha, Koop
AU - Tewarie, Rishi Nandoe
AU - Sedee, Robert-Jan
AU - de Bree, Remco
AU - de Graeff, Alexander
AU - de Vos, Filip
AU - Cuijpers, Pim
AU - Verdonck-de Leeuw, Irma M
N1 - © 2022 The Author(s).
PY - 2022/7/1
Y1 - 2022/7/1
N2 - BACKGROUND: Many patients with incurable cancer have symptoms affecting their health-related quality of life. The eHealth application 'Oncokompas' supports patients to take an active role in managing their palliative care needs, to reduce symptoms and improve health-related quality of life (HRQOL). This randomized controlled trial was conducted to determine the efficacy of Oncokompas compared to care as usual among incurably ill cancer patients with a life expectancy of more than three months.METHODS: Patients were recruited in six hospitals in the Netherlands. Eligible patients were randomly assigned to the intervention (direct access to Oncokompas) or the control group (access to Oncokompas after three months). The primary outcome measure was patient activation (i.e., patients' knowledge, skills and confidence for self-management). Secondary outcomes were general self-efficacy and HRQOL. Measures were assessed at baseline, two weeks after randomization, and three months after the baseline measurement. Linear mixed models were used to compare longitudinal changes between both groups from baseline to the three-month follow-up.FINDINGS: In total, 219 patients were eligible of which 138 patients completed the baseline questionnaire (response rate 63%), and were randomized to the intervention (69) or control group (69). There were no significant differences between the intervention and control group over time in patient activation (estimated difference in change T0-T2; 1·8 (90% CI: -1·0 to 4·7)), neither in general self-efficacy and HRQOL. Of the patients in the intervention group who activated their account, 74% used Oncokompas as intended. The course of patient activation, general self-efficacy, and HRQOL was not significantly different between patients who used Oncokompas as intended versus those who did not.INTERPRETATION: Among incurably ill cancer patients with a life expectancy of more than three months and recruited in the hospital setting, Oncokompas did not significantly improve patient activation, self-efficacy, or HRQOL.FUNDING: ZonMw, Netherlands Organization for Health Research and Development (844001105).
AB - BACKGROUND: Many patients with incurable cancer have symptoms affecting their health-related quality of life. The eHealth application 'Oncokompas' supports patients to take an active role in managing their palliative care needs, to reduce symptoms and improve health-related quality of life (HRQOL). This randomized controlled trial was conducted to determine the efficacy of Oncokompas compared to care as usual among incurably ill cancer patients with a life expectancy of more than three months.METHODS: Patients were recruited in six hospitals in the Netherlands. Eligible patients were randomly assigned to the intervention (direct access to Oncokompas) or the control group (access to Oncokompas after three months). The primary outcome measure was patient activation (i.e., patients' knowledge, skills and confidence for self-management). Secondary outcomes were general self-efficacy and HRQOL. Measures were assessed at baseline, two weeks after randomization, and three months after the baseline measurement. Linear mixed models were used to compare longitudinal changes between both groups from baseline to the three-month follow-up.FINDINGS: In total, 219 patients were eligible of which 138 patients completed the baseline questionnaire (response rate 63%), and were randomized to the intervention (69) or control group (69). There were no significant differences between the intervention and control group over time in patient activation (estimated difference in change T0-T2; 1·8 (90% CI: -1·0 to 4·7)), neither in general self-efficacy and HRQOL. Of the patients in the intervention group who activated their account, 74% used Oncokompas as intended. The course of patient activation, general self-efficacy, and HRQOL was not significantly different between patients who used Oncokompas as intended versus those who did not.INTERPRETATION: Among incurably ill cancer patients with a life expectancy of more than three months and recruited in the hospital setting, Oncokompas did not significantly improve patient activation, self-efficacy, or HRQOL.FUNDING: ZonMw, Netherlands Organization for Health Research and Development (844001105).
KW - Incurable cancer
KW - Palliative care
KW - Psychosocial oncology
KW - Supportive care
KW - eHealth
UR - http://www.scopus.com/inward/record.url?scp=85129628906&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.lanepe.2022.100390
DO - https://doi.org/10.1016/j.lanepe.2022.100390
M3 - Article
C2 - 35496496
SN - 2666-7762
VL - 18
SP - 100390
JO - The Lancet Regional Health - Europe
JF - The Lancet Regional Health - Europe
M1 - 100390
ER -